WATERTOWN, Mass.--(BUSINESS WIRE)--Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA), a leader in the development of RNAi-based therapeutics, presented data from its preclinical program in primary hyperoxaluria type 1 (PH1) in a poster session at the 10th Annual Meeting of the Oligonucleotide Therapeutics Society (OTS), held in San Diego, October 12-15, 2014. The data confirm the therapeutic potential of DCR-PH1, the company’s investigational treatment for PH1, a rare, inherited liver disorder that often results in kidney failure.
Help employers find you! Check out all the jobs and post your resume.
